João L. Carapinha, Ph.D.
Table of Contents
I'm interested in the potential benefits of using composite NNT CPEA for evaluating therapies in cardiovascular and kidney disease. What do you think should be the main focus for utilizing this method effectively? Share your insights by voting below!
What should be the main focus for effectively using composite NNT CPEA in therapy evaluation?
Integrate in Payer Guidelines
Expand Clinical Endpoints
Develop Fair Pricing Standards
Enhance Patient Discussions
Syenza News
TWITTER
LINKEDIN
